Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer

22 Oct 2024

Abstract excerpt

Prostate cancer is the second leading cause of male cancer death in the U.S. Current immune checkpoint inhibitor-based immunotherapies have improved survival for many malignancies; however, they have failed to prolong survival for prostate cancer. Siglecs (sialic acid-binding immunoglobulin-like lectins) are expressed on immune cells and regulate their function. Siglec-7 and Siglec-9 contribute to immune evasion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Galectins and Cancer Biology
Share to Glycosylation and Glycoproteins Research
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39436703
DOI: 10.1172/jci180282

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancerPMID 39436703Read ↗

The Androgen Receptor and MYC synergise to modulate the synthesis of Siglec-7 ligands in prostate cancerSemantic proximity Read ↗

Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamilySemantic proximity Read ↗

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockadeSemantic proximity Read ↗

Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.Semantic proximity Read ↗

CRISPR activation screens map the genomic landscape of cancer glycome remodelingSemantic proximity Read ↗

Targeting glycosylated antigens on cancer cells using siglec‐7/9‐based CAR T‐cellsSemantic proximity Read ↗

Siglec-15 is a glyco-immune checkpoint in prostate cancer regulating immune evasion and metastasisSemantic proximity Read ↗

A Mutation in the Carbohydrate Recognition Domain Drives a Phenotypic Switch in the Role of Galectin-7 in Prostate Cancer.Semantic proximity Read ↗

Insights into Siglec‐7 Binding to Gangliosides: NMR Protein Assignment and the Impact of Ligand FlexibilitySemantic proximity Read ↗

Unravelling CD24 ‐ Siglec‐10 pathway: Cancer immunotherapy from basic science to clinical studiesSemantic proximity Read ↗

Cloning and Characterization of Siglec-10, a Novel Sialic Acid Binding Member of the Ig Superfamily, from Human Dendritic CellsSemantic proximity Read ↗

The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.